Alnylam Pharmaceuticals, Inc. (ALNY) News

Alnylam Pharmaceuticals, Inc. (ALNY): $233.85

4.46 (+1.94%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALNY to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

Filter ALNY News Items

ALNY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ALNY News Highlights

  • For ALNY, its 30 day story count is now at 38.
  • Over the past 17 days, the trend for ALNY's stories per day has been choppy and unclear. It has oscillated between 1 and 14.
  • GOLD, AB and AG are the most mentioned tickers in articles about ALNY.

Latest ALNY News From Around the Web

Below are the latest news stories about Alnylam Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNY as an investment opportunity.

Alnylam Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha | February 15, 2022

Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Expected To Breakeven In The Medium-Term

We feel now is a pretty good time to analyse Alnylam Pharmaceuticals, Inc.'s ( NASDAQ:ALNY ) business as it appears the...

Yahoo | February 15, 2022

BMO Capital Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)

BMO Capital analyst Gary Nachman maintained a Hold rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $175.00. The company's shares closed last Friday at $148.79. According to TipRanks.com, Nachman has 0 stars on 0-5 stars ranking scale with an average return of -4.4% and a 42.7% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Jazz Pharmaceuticals, and Horizon Therapeutics. Currently, the analyst consensus on Alnylam Pharma is a Strong Buy with an average price target of $210.53, implying a 41.0% upside from current levels.

Brian Anderson on TipRanks | February 11, 2022

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Cigna (CI) and SCYNEXIS (SCYX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY – Research Report), Cigna (CI – Research Report) and SCYNEXIS (SCYX – Research Report). Alnylam Pharma (ALNY) In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Alnylam Pharma, with a price target of $200.00. The company's shares closed last Thursday at $150.86. According to TipRanks.

Brian Anderson on TipRanks | February 11, 2022

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Dyadic International (DYAI) and SCYNEXIS (SCYX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY – Research Report), Dyadic International (DYAI – Research Report) and SCYNEXIS (SCYX – Research Report). Alnylam Pharma (ALNY) In a report released today, Zhiqiang Shu from Berenberg Bank maintained a Hold rating on Alnylam Pharma, with a price target of $154.00. The company's shares closed last Thursday at $150.86. According to TipRanks.

Christine Brown on TipRanks | February 11, 2022

Expert Ratings For Alnylam Pharmaceuticals

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ: ALNY ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 3 2 0 0 Last 30D 0 0 1 0 0 1M Ago 2 1 1 0 0 2M Ago 0 1 0 0 0 3M Ago 2 1 0 0 0 In the last 3 months, 9 analysts have offered 12-month price targets for Alnylam Pharmaceuticals. The company has an average price target of $206.44 with a high of $350.00 and a low of $103.00. Below is a summary of how these 9 analysts rated Alnylam Pharmaceuticals over the past … Full story available on Benzinga.com

Benzinga | February 11, 2022

Alnylam maintains bullish views at Street firms following Q4 revenue beat

Several Street firms are maintaining bullish views on Alnylam Pharmaceuticals following the biotech Q4 2021 earnings results Thursday.

Seeking Alpha | February 11, 2022

Alnylam's (ALNY) Q4 Earnings Miss Estimates, Revenues Beat

Alnylam's (ALNY) earnings fall shy of estimates in the fourth quarter of 2021 while revenues beat the same. The company issues 2022 guidance for net product revenues.

Yahoo | February 11, 2022

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Biogen (BIIB)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNY – Research Report) and Biogen (BIIB – Research Report) with bullish sentiments. Alnylam Pharma (ALNY) Needham analyst Joseph Stringer reiterated a Buy rating on Alnylam Pharma today and set a price target of $205.00. The company's shares closed last Thursday at $153.94. According to TipRanks.

Brian Anderson on TipRanks | February 10, 2022

Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B

Alnylam Pharmaceuticals Inc''s (NASDAQ: ALNY ) Q4 product revenues increased 76% Y/Y to $198.5 million , primarily due to the continued global expansion of Onpattro and Givlaari, and sales from a third commercial product, Oxlumo. Collaborations sales increased 18%, primarily due to increased revenue from collaboration agreements with Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) and Novartis AG (NYSE: Full story available on Benzinga.com

Benzinga | February 10, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5539 seconds.